SWOBY / Swedish Orphan Biovitrum AB (publ) - Depositary Receipt (Common Stock) - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 4 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 4 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name

Stockholm, Sweden, 24 June, 2023

EX-99.(a)(5)(iv) Exhibit (a)(5)(iv) Press release Stockholm, Sweden, 24 June, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISD

Stockholm, Sweden, 26 June, 2023

EX-99.(a)(5)(v) Exhibit (a)(5)(v) Press release Stockholm, Sweden, 26 June, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 3 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 3 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 2 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 2 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 1 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 1 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name

Offer to Purchase for Cash All Outstanding Shares of Common Stock CTI BIOPHARMA CORP. $9.10 Per Share Pursuant to the Offer to Purchase dated May 25, 2023 CLEOPATRA ACQUISITION CORP. a wholly owned, indirect subsidiary of SWEDISH ORPHAN BIOVITRUM AB

Form of Letter to Clients for use by Brokers, Dealers, etc Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP.

LETTER OF TRANSMITTAL to Tender Shares of Common Stock CTI BIOPHARMA CORP. Pursuant to the Offer to Purchase dated May 25, 2023 CLEOPATRA ACQUISITION CORP. a wholly owned, indirect subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL)

Form of Letter of Transmittal Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of CTI BIOPHARMA CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQU

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name of Filing Person—

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defi

Summary Advertisement Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

Stockholm, Sweden, May 25, 2023

EX-99.(a)(5)(iii) Exhibit (a)(5)(iii) Press release Stockholm, Sweden, May 25, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURIS

NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of CTI BIOPHARMA CORP. Pursuant to the Offer to Purchase dated May 25, 2023 CLEOPATRA ACQUISITION CORP. a wholly owned, indirect subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL)

Form of Notice of Guaranteed Delivery Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of CTI BIOPHARMA CORP.

Offer to Purchase for Cash All Outstanding Shares of Common Stock CTI BIOPHARMA CORP. $9.10 Per Share Pursuant to the Offer to Purchase dated May 25, 2023 CLEOPATRA ACQUISITION CORP. a wholly owned, indirect subsidiary of SWEDISH ORPHAN BIOVITRUM AB

Form of Letter to Brokers, Dealers, Commercial banks, Trust Companies and Other Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP.

Offer to Purchase for Cash All Outstanding Shares of Common Stock CTI BIOPHARMA CORP. $9.10 Per Share CLEOPATRA ACQUISITION CORP. a wholly owned indirect subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL)

Offer to Purchase Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP.

EUR 800,000,000 EUR TERM LOAN AND MULTICURRENCY REVOLVING CREDIT FACILITIES

EX-99.(b)(2) Exhibit (b)(2) CONFIDENTIAL To: Swedish Orphan Biovitrum AB (publ) (the “Company”) For the attention of Henrik Stenqvist and Erik Krohn 9 May 2023 EUR 800,000,000 EUR TERM LOAN AND MULTICURRENCY REVOLVING CREDIT FACILITIES We Bank of America Europe Designated Activity Company and Danske Bank A/S (together the underwriters, bookrunners and mandated lead arrangers and hereafter referred

SEK 8,000,000,000 EQUITY BRIDGE FACILITY

EX-99.(b)(1) Exhibit (b)(1) CONFIDENTIAL To: Swedish Orphan Biovitrum AB (publ) (the “Company”) For the attention of Henrik Stenqvist and Erik Krohn 9 May 2023 SEK 8,000,000,000 EQUITY BRIDGE FACILITY We Bank of America Europe Designated Activity Company and Danske Bank A/S (together the underwriters, bookrunners and mandated lead arrangers and hereafter referred to as the “Banks” in such roles) a

Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person — Offeror) An indirect wholly owned subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUB

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CTI BIOPHARMA CORP.

MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

EX-99.(d)(3) Exhibit (d)(3) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT THIS MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT (“Agreement”) is entered into as of March 3, 2023 (the “Effective Date”), by and between CTI BioPharma Corp., a Delaware corporation having its principal place of business located at 3101 Western Avenue, Suite 800, Seattle, WA 98121, and its affiliates and subsidiaries, and Swedish Or

Stockholm, Sweden, 10 Maj, 2023

EX-99.1 Exhibit 99.1 Press release Stockholm, Sweden, 10 Maj, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. Sobi to

Additional Information and Where to Find It The Offer for all of the outstanding shares of common stock (the “Shares”) of CTI BioPharma Corp. (the “Company”) referenced in this communication has not yet commenced. This communication is for informatio

EX-99.2 10th May, 2023 Acquisition of CTI Biopharma Expanding Sobi’s position in rare haematology Exhibit 99.2 This presentation contains forward-looking statements by Sobi that involve risks and uncertainties and reflect Sobi’s judgment as of the date of this presentation. These forward-looking statements generally are identified by words such as “believe,” “project,” “expect,” “anticipate,” “est

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQU

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) An Indirect Wholly Owned Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name of Filing Person

SELB / Selecta Biosciences, Inc. / Swedish Orphan Biovitrum AB (publ) - SC 13G Passive Investment

SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Selecta Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 par value per shar

Stockholm, Sweden, 9 November 2019

Exhibit (a)(5)(D) PRESS RELEASE Stockholm, Sweden, 9 November 2019 Sobi successfully completes tender offer for all outstanding shares of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that its indirect wholly owned subsidiary Dragonfly Acquisition Corp.

SWTUY / Swedish Orphan Biovitrum AB SC TO-T/A - - AMENDMENT NO. 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Su

Stockholm, Sweden, 12 November 2019

Exhibit (a)(5)(E) PRESS RELEASE Stockholm, Sweden, 12 November 2019 Sobi successfully completes acquisition of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Dova Pharmaceuticals, Inc.

SWTUY / Swedish Orphan Biovitrum AB SC TO-T/A - - AMENDMENT NO. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Su

1

Exhibit (a)(5)(C) PRESS RELEASE Stockholm, Sweden, 11 October 2019 Sobi commences tender offer for all outstanding shares of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has commenced a tender offer through its indirect wholly owned subsidiary Dragonfly Acquisition Corp.

TENDER AND SUPPORT AGREEMENT

EX-99.(D)(4) 10 a2239851zex-99d4.htm EX-99.(D)(4) Exhibit (d)(4) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of

August 19, 2019

Exhibit (d)(5) STRICTLY CONFIDENTIAL August 19, 2019 CONFIDENTIAL Swedish Orphan Biovitrum AB (publ) Tomtebodavägen 23A SE-112 76 Stockholm Sweden Attn: Mr.

SWTUY / Swedish Orphan Biovitrum AB SC TO-T - - SC TO-T

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

TENDER AND SUPPORT AGREEMENT

EX-99.(D)(3) 9 a2239851zex-99d3.htm EX-99.(D)(3) Exhibit (d)(3) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of P

Letter of Transmittal to Tender Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cash payment o

QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of DOVA PHARMACEUTICALS, INC.

Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the

Exhibit (a)(1)(c) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC.

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by

EX-99.(A)(1)(F) 7 a2239851zex-99a1f.htm EX-99.(A)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated October 11, 2019, and the related Letter of Tr

Offer to Purchase for Cash All Outstanding Shares of Common Stock of Dova Pharmaceuticals, Inc. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cas

QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Dova Pharmaceuticals, Inc.

Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cas

Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC.

Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. at $27.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive a cas

Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC.

30th September 2019 Introduction to Sobi Sobi in brief 2 Biopharmaceutical company with a focus on rare diseasesBusiness areas:HaematologyImmunologyPresent in more than 25 countries, delivering treatments to patients in over 70 countries around the w

Exhibit 99.1 The following presentation was made available to employees of Dova Pharmaceuticals, Inc.: Notice to Investors The tender offer for the outstanding shares of Dova Pharmaceuticals Inc. (“Dova”) common stock has not yet commenced. This presentation is being given to Dova’s employees for informational purposes only and such presentation is neither an offer to purchase nor a solicitation o

SWTUY / Swedish Orphan Biovitrum AB SC TO-C - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of SWEDIS

Stockholm, Sweden, 30 September 2019

Exhibit 99.1 PRESS RELEASE Stockholm, Sweden, 30 September 2019 Sobi to acquire Dova Pharmaceuticals creating a global growth platform in haematology Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in ca

SWTUY / Swedish Orphan Biovitrum AB SC TO-C - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of SWEDIS